Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Biochemical Pharmacology

Volumn 52, Issue 1, 1996, Pages 29-34

  McNaught, Kevin St P ^a   Thull, Ulrike ^b   Carrupt, Pierre Alain ^b   Altomare, Cosimo ^c   Cellamare, Saverio ^c   Carotti, Angelo ^c   Testa, Bernard ^b   Jenner, Peter ^a   Marsden, C David ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BARI   (Italy)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

1,2,3,4 tetrahydroisoquinoline; 1 methyl 4 phenyl 1,2,3,6 tetra hydropyridine; 1 methyl 4 phenylpyridinium; Parkinson's disease; structure activ ity relationship; synaptosomes

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DIHYDROISOQUINOLINE DERIVATIVE; DOPAMINE; ISOQUINOLINE DERIVATIVE; NEUROTOXIN; RADIOISOTOPE; SALSOLINOL; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; DOPAMINE UPTAKE INHIBITOR; TRITIUM;

ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DRUG UPTAKE; MALE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG EFFECT; METABOLISM; SYNAPTOSOME; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DOPAMINE UPTAKE INHIBITORS; ISOQUINOLINES; MALE; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES; TRITIUM;

EID: 0029666242     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00133-5     Document Type: Article

References (40)

1. Chiba K, Trevor AJ and Castagnoli NJr, Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574-578, 1984.
2. Javitch JA, D'Amato RJ, Strittmatter SM and Snyder SH, Parkinsonism inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173-2177, 1985.
3. Ramsay RR, Salach JI, Dadgar J and Singer TP, Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem Biophys Res Commun 135: 269-275, 1986.
4. +) causes ATP depletion in isolated hepatocytes. Biochem Biophys Res Commun 137: 310-315, 1986.
5. Mizuno Y, Saitoh T and Sone N, Inhibition of mitochondrial α-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun 143: 971-976, 1987.
6. Nicklas WJ, Vyas I and Heikkila RE, Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36: 2503-2508, 1985.
7. Kohno M, Ohta S and Hirobe M, Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem Biophys Res Commun 140: 448-454, 1986.
8. Ohta S, Kohno M, Makino Y, Tachikawa O and Hirobe M, Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain: relation to Parkinson's disease. Biochem Res 8: 453-456, 1987.
9. Niwa T, Nakeda N, Yoshizumi H, Tatematsu A, Yoshida M, Dostert P, Naoi M and Nagatsu T, (1991) Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines in parkinsonian and normal human brains. Biochem Biophys Res Commun 177: 603-609, 1991.
10. Niwa T, Takeda N, Hashizume Y and Nagatsu T, Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroisoquinoline in parkinsonian and normal human brains. Biochem Biophys Res Commun 144: 1084-1089, 1989.
11. Deitrich R and Erwin V, Biogenic amine-aldehyde condensation products: tetrahydroisoquinolines and tryptolines (β-carbolines). Annu Rev Pharmacol Toxicol 20: 55-80, 1980.
12. Naoi M, Matsurra S, Parvez H, Takahashi T, Hirata Y, Minami M and Nagatsu T, Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinoline into the N-methyl-isoquinolinium ion by monoamine oxidase. J Neurochem 52: 653-655, 1989.
13. Naoi M, Matsuura S, Takahashi T and Nagatsu T, A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydoisoquinoline into N-methyl-1,2,3,4-tetrahydoisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. Biochem Biophys Res Commun 161: 1213-1219, 1989.
14. Makino Y, Ohta S, Tachikawa O and Hirobe M, Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson's disease. Life Sci 43: 373-378, 1988.
15. Niwa T, Yoshizumo H, Tatematsu A, Matsuura S and Nagatsu T, Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. J Chromatogr Biomed Appl 493: 347-352, 1989.
16. Kikuchi K, Nagatsu Y, Makino Y, Mashino T, Ohta S and Hirobe M, Metabolism and penetration through the blood-brain barrier of parkinsonism-related compounds: 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. Drug Metab Dispos 19: 257-262, 1991.
17. McNaught KStP, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P and Marsden CD, Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 50: 1903-1911, 1995.
18. McNaught KStP, Altomare C, Cellamare S, Carotti A, Thull U, Carrupt PA, Testa B, Jenner P and Marsden CD, Inhibition of α-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroreport 6: 1105-1108, 1995.
19. McNaught KStP, Altomare C, Cellamare S, Carotti A, Thull U, Carrupt PA, Testa B, Jenner P and Marsden CD, Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on mitochondrial respiration. Biochem Pharmacol 51: 1503-1511, 1996.
20. Sayre LM, Wang F, Arora PK, Riachi NJ, Harik SI and Hoppel CL, Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium-like substances. J Neurochem 57: 2106-2115, 1991.
21. Suzuki K, Mizuno Y and Yoshida M, Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline. Biochem Biophys Res Commun 162: 1541-1545, 1989.
22. Suzuki K, Mizuno Y and Yoshida M, Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain. Neurochem Res 7: 705-710, 1990.
23. Heikkila R, Cohen G and Dembiec D, Tetrahydroisoquinoline alkaloids: uptake by rat brain homogenates and inhibition of catecholamine uptake. J Pharmacol Exp Ther 179: 250-258, 1971.
24. Hirata Y, Minami M, Naoi M and Nagatsu T, Studies on the uptake of N-methylisoquinolinium ion into rat striatal slices using high-performance liquid chromatography with fluorimetric detection. J Chromatogr 503: 189-195, 1990.
25. Liptrot J, Holdup D and Phillipson O, 1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol depletes catecholamines in rat brain. J Neurochem 61: 2199-2206, 1993.
26. +) destroys cultured mesencephalic dopamine neurons. Biogenic Amines 8: 61-67, 1991.
27. +) and tetrahydroisoquinoline derivatives on dopaminergic neurons in ventral mesencephalic-striatal co-culture. Neurodegeneration 3: 33-42, 1994.
28. Ogawa M, Araki M, Nagatsu I, Nagatsu T and Yoshida M, The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57/BL mice: immunohistochemical studies-tyrosine hydroxylase. Biogenic Amines 6: 427-436, 1989.
29. Glowinski J and Iversen LL, Regional studies of catecholamines in the rat brain-1. J Neurochem 13: 655-669, 1966.
30. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N and Ikebe S (1994) An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neural 35: 204-210, 1994.
31. 1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55: 2142-2145, 1990.
32. Drucker G, Raikoff K, Neafsey EJ and Collins MA, Dopamine uptake inhibitory capacities of β-carboline and 3,4-dihydro-β-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res 509: 125-133, 1990.
33. 3H]5-hydroxytryptamine in neostriatal synaptosomal preparations. J Neurochem 44: 310-313, 1985.
34. Javitch JA and Snyder SH, Uptake of MPP(+) by dopamine neurons explain selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106: 455-456, 1985.
35. +, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128: 1228-1232, 1985.
36. Mayer RA, Kindt MV and Heikkila RE, Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem 47: 1073-1079, 1986.
37. 3H]GBR 12783 binding to the dopamine uptake complex in rat striatal. Neurosci Lett 96: 335-339, 1989.
38. +) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake. Eur J Pharmacol 166: 65-74, 1989.
39. +), the cytotoxic metabolite of the neurotoxin MPTP. Life Sci 46: 379-390, 1990.
40. McNaught KStP, Altomare C, Cellamare S, Carotti A, Thull U, Carrupt PA, Testa B, Jenner P and Marsden CD. Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurosci Lett 206: 37-40, 1996.